Virtu Financial’s Propanc Biopharma PPCB Stock Holding History

Virtu Financial’s Portfolio PPCB Stock Details PPCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4K	Buy	+1,630	New	+$9.67K	﹤0.01%	1524
2025 Q4	–	Sell	-1,667	Closed	-$71K	–	2453
2025 Q3	$71K	Buy	+1,667	New	+$108K	﹤0.01%	1088

Other funds holding PPCB

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

SCA

Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Virtu Financial's PPCB Position: Q1 2026 in Review

Virtu Financial opened a new position in Propanc Biopharma (PPCB) in Q1 2026: 1,630 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #1524 among its holdings. This is a return to the name: Virtu Financial previously reported a position in PPCB as recently as Q3 2025.

Virtu Financial first reported a position in PPCB in Q3 2025 and has held it in 2 quarters since. The position peaked at $71K in Q3 2025. 6 funds tracked by Wall St. Rank hold PPCB as of Q1 2026.

Virtu Financial held 1,630 shares of Propanc Biopharma worth $4K as of Q1 2026.
Propanc Biopharma was a new Virtu Financial position in Q1 2026.
Propanc Biopharma made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1524 holding.
Virtu Financial first reported a position in Propanc Biopharma in Q3 2025 and has held it in 2 quarters since.
Virtu Financial's Propanc Biopharma position peaked at $71K in Q3 2025.
6 funds tracked by Wall St. Rank held Propanc Biopharma as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.